Design of rapid and quantitative biosensors with computational protein design

The National Institute of General Medical Sciences awarded Monod Bio, Inc. $377,260 for design and development of rapid, quantitative biosensors using computational protein design, with an award date of August 1, 2026.

Monod Bio is advancing its NovoLISA technology to transform biosensing methods in life sciences research. The work addresses limitations of traditional biosensing approaches such as ELISAs, which require 90–270 minutes for results, involve complex procedures, demand extensive antibody development time, and carry risk of cross-reactivity due to insufficient antibody validation. The NovoLISA assay offers a rapid alternative.

This is a Project Grant under the Biomedical Research and Research Training program (CFDA 93.859), which supports basic research to increase understanding of biological processes and lay foundation for advances in disease diagnosis, treatment, and prevention. Performance takes place in Seattle, Washington, with a period of performance ending May 31, 2027.

Abstract

Monod BIO's fast-track proposal aims to advance the novolisa™ technology, transforming biosensing methods in life sciences research. Traditional biosensing approaches, such as elisas, face significant limitations, including prolonged time-to-results (90-270 minutes), complex procedures, extensive antibody development times, and the risk of cross-reactivity due to insufficient antibody validation. In contrast, monod BIO's novolisa assay offers a rapid (